Delayed reactivation of chronic infantile neurologic, cutaneous, articular syndrome (CINCA) in a patient with somatic mosaicism of CIAS1/NLRP3 gene after withdrawal of anti-IL-1 beta therapy

Clinical and Experimental Rheumatology

Volumn 33, Issue 5, 2015, Pages 766-766

  Paloni, G ^a   Pastore, Serena ^a   Tommasini, A ^a   Lepore, L ^b   Taddio, A ^a,b  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; CANAKINUMAB; CRYOPYRIN; IMMUNOGLOBULIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; CARRIER PROTEIN; IL1B PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; NLRP3 PROTEIN, HUMAN;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD ANALYSIS; BONE BIOPSY; BONE SWELLING; CASE REPORT; CHONDROID DYSOSTOSIS; CIAS1 GENE; CINCA SYNDROME; COXITIS; DRUG SUBSTITUTION; DYSOSTOSIS; ERYTHEMA; FEMALE; FEVER; HEADACHE; HEPATOSPLENOMEGALY; HUMAN; IRON DEFICIENCY ANEMIA; KNEE ARTHRITIS; LEUKOCYTOSIS; LYMPHADENOPATHY; MOSAICISM; MUTATIONAL ANALYSIS; PAPILLEDEMA; PRIORITY JOURNAL; RELAPSE; URTICARIA; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DRUG ADMINISTRATION; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; PHENOTYPE; RECURRENT DISEASE; REMISSION; TIME; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CARRIER PROTEINS; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MOSAICISM; PHENOTYPE; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84944384898     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. PRIEUR AM, GRISCELLI C, LAMPERT F et al.: A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome: a specific entity analysed in 30 patients. Scand J Rheumatol 1987; 66: 57-68.
2. PRIEUR AM: A recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy. Clin Exp Rheumatol 2001; 19: 103-6.
3. MARTINON F, TSCHOPP J: Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004; 117: 561-74.
4. NEVEN B, CALLEBAUT I, PRIEUR AM et al.: Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disordes CINCA/NOMID, MWS, and FCU. Blood 2004; 103: 2809-15.
5. AKSENTIJEVICH I, NOWAK M, MALLAH M et al.: De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46: 3340-8.
6. CAROLI F, PONTILLO A, D'OSUALDO A et al.: Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology (Oxford) 2007; 46: 473-8.
7. LACHMANN HJ, KONE-PAUT I, KUEMMERLEDESCHNER JB et al.: Use of canakinumab in the cryopyrinassociated periodic syndrome. N Engl J Med 2009; 360: 2416-25.
8. GOLDBACH-MANSKY R, DAILEY NJ, CANNA SW et al.: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355: 581-92.
9. BAROJA-MAZO A, MARTíN-SáNCHEZ F, GOMEZ AI et al.: The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol 2014; 15: 738-48.